“This quarter was record-breaking for Aurora, driven by all-time highs in global medical net revenue, net income, adjusted EBITDA, and free cash flow,” said Miguel Martin, Aurora's executive chairman and CEO. The company also posted a net income of CA$31.2 million, a 282% year-over-year increase, and an adjusted EBITDA of CA$23.1 million, up 316%.
Cannabis Stocks Rally In Sympathy?
The strong earnings report triggered a broader rally in the cannabis sector, with several companies experiencing notable gains:
Investors appear to be reacting positively to Aurora's performance, particularly its growing international medical cannabis revenues and improved profitability.
Do Trade Tensions Play A Role?
As Aurora continues to expand its medical cannabis footprint globally, investors are closely watching whether the company can sustain its momentum in upcoming quarters.
Illustration made with Canva.
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
